Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.

Pharmaceutical

Evotec

Craig Johnstone

Laetitia Rouxel

Cord Dohrmann

Hans-Ulrich Wolf

The Scientific Research Team at Evotec is dedicated to advancing drug discovery and development through innovative research and collaboration. Composed of experts in various fields, including protein production, biomarker development, and bioinformatics, the team works on both internal projects and partnerships to push the boundaries of medical science. Their efforts are central to the identification and validation of drug candidates, with a focus on harnessing technologies like induced pluripotent stem cells (iPSC) and contributing to clinical advancements across multiple therapeutic areas.

Scientific Research Team

About

Team members

Other teams at Evotec

Leadership Team

Business Development and Strategy Team